Table 2. Pharmacogenomic interaction guidelines associated with error rates or hallucination generation. This table displays pharmacogenomic interaction guidelines linked to error rates or hallucination generation during classification. It details the specific guidelines, artificial intelligence (AI) tool thresholds used, large language model (LLM) answers, manual review results, and the reasons for discrepancies with human labels. Discrepancies were mainly due to conflicting classifications for different genotypes or model-generated information beyond the scope of the guidelines.

Pharmacogenomic interaction guidelines	AI tool threshold used	LLM answers	Manual review result	Guideline content	Reasons for discrepancies with human labels (hallucinations)
No.254 trimipramine - CYP2D6	Repeated cross-comparisons	Consider dosage modification	Change medication	CYP2D6 UM/PMs, CYP2C19 UM/RM/PMs: Use an alternative drug. CYP2D6 or CYP2C19 PMs (if used): Reduce dose by 50%. CYP2D6 IMs: Reduce dose by 25%.	Guideline prompts conflicting classifications for different genotypes
No.211 imipramine - CYP2D6	Agreement-threshold strategy	Consider dosage modification	Change medication	CYP2D6 UM/PMs, CYP2C19 UM/RM/PMs: Use an alternative drug. CYP2D6 or CYP2C19 PMs (if used): Reduce dose by 50%. CYP2D6 IMs: Reduce dose by 25%.	Guideline prompts conflicting classifications for different genotypes
No.278 daunorubicin - SLC28A3	Agreement-threshold strategy	Consider dosage modification	Other	Perform pharmacogenomic testing for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 (rs17863783)	Model-generated extraneous information beyond guideline content